Acadia Pharma (ACAD) Tops Q2 EPS by 2c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $29.21 +2.67%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
BMNM, KG, NHC, More
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
BMNM, KG, NHC, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of $0.16, $0.02 better than the analyst estimate of $0.14. Revenue for the quarter came in at $264.6 million versus the consensus estimate of $262.44 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rockstar Energy founder seeks CEO role at Celsius Holdings
- Acadia Pharmaceuticals (ACAD) PT Raised to $37 at RBC Capital on 'Strong Sales'
- SpyGlass Pharma (SGP) Reports Q2 Loss of $0.59
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
